Primary Efficacy Endpoint
garadacimab, obesity, death, comorbidity
REGRESSION, OBESITY
There was no difference in the proportion of patients who progressed to TI or death before TI from randomisation to Day 28 between garadacimab and placebo groups [22.2% vs 26.2%; adjusted risk difference (ARD) 4.54% (95% CI 19.3, 10.2); ARD and 95% confidence limits for incidence of clinical outcomes indicative of COVID-19 severity for garadacimab—placebo. Firth logistic regression model includes treatment, age (continuous), sex and baseline comorbidity factors (presence of obesity [BMI ≥ 30 kg/mSubgroup analyses of the primary efficacy endpoint based on age group, sex and baseline comorbidities yielded no meaningful differences between patients receiving garadacimab and placebo.